Metastatic carcinomatous cirrhosis from diffuse breast cancer liver metastasis: a case report.

Abdom Radiol (NY)Apr 10, 2026 (epub)

Takahiro Komori, Norihide Yoneda, Kanako Terada et al.

✦ AI-curated · Sources linked

Case in brief

A woman in her 50s with a history of breast cancer treated by mastectomy and adjuvant hormone therapy, followed by resection of a local recurrence, presented with fatigue and abdominal distension. CT showed massive ascites, and contrast-enhanced CT and MRI demonstrated cirrhosis-like liver morphology. With no prior documented liver metastases or chemotherapy, metastatic carcinomatous cirrhosis was suspected. Transjugular biopsy confirmed extensive tumor infiltration of portal areas with fibrosis and scar formation dissecting the hepatic parenchyma.

What made this case unusual

Imaging resembled pseudocirrhosis, but biopsy showed diffuse metastatic tumor infiltration with fibrosis and scar formation, supporting metastatic carcinomatous cirrhosis—a distinct pathophysiology despite similar morphology.

Diagnostic / clinical pearl

In a patient with malignancy and rapidly progressive liver dysfunction, cirrhosis-like imaging should prompt consideration of metastatic carcinomatous cirrhosis; biopsy can distinguish it from pseudocirrhosis.

Source

Published in Abdom Radiol (NY). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.